The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,728,096.00 cost-plus-fixed-fee definitive contract to Myelo Therapeutics GmbH, a for-profit limited liability company, for the development of MYELO001 as an orally applied medical countermeasure to treat hematopoietic acute radiation syndrome. This contract, which has a completion date of January 16, 2025, stems from a Broad Agency Announcement seeking proposals to develop safe and effective medical countermeasures that can mitigate and/or treat tissue injuries from ionizing radiation exposure in a radiological or nuclear incident, with the goal of reducing radiation-associated morbidities and mortalities when strategic national stockpile drugs may not be available within the first 24 hours. The contract does not have a set-aside designation.
Generated 1/17/25, 9:16 AM